Adding carotid-artery stenting—but not carotid endarterectomy—to intensive medical management reduced the risk of stroke or death in patients with high-grade asymptomatic carotid stenosis. In two parallel, observer-blinded trials including more than 2,400 participants with ≥70% stenosis, the 4-year incidence of the primary composite outcome (any stroke or death from randomization to 44 days, or ipsilateral ischemic stroke during the remaining follow-up period up to 4 years) was significantly lower with stenting than with medical therapy alone (2.8% vs. 6.0%), whereas endarterectomy showed no significant advantage over medical therapy (3.7% vs. 5.3%). Early perioperative risks differed across interventions: in the stenting trial, eight events (seven strokes, one death) occurred during the first 44 days in the stenting group versus none in the medical-therapy group, and in the endarterectomy trial, nine strokes occurred in the endarterectomy group versus three with medical therapy. Overall, these results suggest that in asymptomatic high-grade carotid stenosis, stenting can offer added protection against future ipsilateral stroke, whereas endarterectomy does not provide a clear incremental benefit over intensive medical therapy alone. The benefit from revascularization of asymptomatic carotid stenosis for stroke prevention has become small with improved medical therapy. Source: https://www.nejm.org/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.